Chris Manfuso is the national sales director of Nubratorix RX and Enovachem Pharmaceuticals. Drawing on years of experience in the healthcare sector, Chris Manfuso oversees the business expansion and product marketing as well as strategic partnerships aimed at improving revenue generation.
One of the fastest-growing trends in the pharmaceutical industry is the advent of personalized medicine. Also known as precision medicine, personalized medicine involves tailoring therapies and treatments to individual patients based on their predicted response to the therapy. Market research from BIS Research suggests that precision therapies will likely see an increase of 33 percent by 2025.
For manufacturers, the rise of precision medicine has several implications. Small production runs of targeted therapies will become more common and more profitable. Additionally, production schedules will have to shift to a made-to-order basis, at least in part. Moreover, smaller and more agile facilities will be better positioned to meet the needs of precision medicine than giant production plants with specialized capabilities.
One of the fastest-growing trends in the pharmaceutical industry is the advent of personalized medicine. Also known as precision medicine, personalized medicine involves tailoring therapies and treatments to individual patients based on their predicted response to the therapy. Market research from BIS Research suggests that precision therapies will likely see an increase of 33 percent by 2025.
For manufacturers, the rise of precision medicine has several implications. Small production runs of targeted therapies will become more common and more profitable. Additionally, production schedules will have to shift to a made-to-order basis, at least in part. Moreover, smaller and more agile facilities will be better positioned to meet the needs of precision medicine than giant production plants with specialized capabilities.
